Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.
van der Boor SC, Smit MJ, van Beek SW, Ramjith J, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Pickkers P, Wu Y, Locke E, Lee SM, Aponte J, King CR, Birkett AJ, Miura K, Ayorinde MA, Sauerwein RW, Ter Heine R, Ockenhouse CF, Bousema T, Jore MM, McCall MBB.
van der Boor SC, et al. Among authors: sauerwein rw.
Lancet Infect Dis. 2022 Nov;22(11):1596-1605. doi: 10.1016/S1473-3099(22)00428-5. Epub 2022 Aug 10.
Lancet Infect Dis. 2022.
PMID: 35963275
Free PMC article.
Clinical Trial.